id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2011-D-0872-0023,FDA,FDA-2011-D-0872,Guidance for Industry Considerations for Use of Histopathology and Its Associated Methodologies to Support Biomarker Qualification,Other,Guidance,2016-05-16T04:00:00Z,2016,5,2016-05-16T04:00:00Z,,2024-11-07T23:42:16Z,,1,0,0900006481fd0aff
FDA-2011-D-0872-0022,FDA,FDA-2011-D-0872,Considerations for Use of Histopathology and Its Associated Methodologies To Support Biomarker Qualification; Guidance for Industry; Availability,Notice,Notice of Availability,2016-05-16T04:00:00Z,2016,5,2016-05-16T04:00:00Z,,2016-05-16T13:07:01Z,2016-11438,0,0,0900006481fd0f0c
FDA-2011-D-0872-0002,FDA,FDA-2011-D-0872,Draft Guidance for Industry on Use of Histology in Biomarker Qualification Studies,Other,Guidance,2011-12-30T05:00:00Z,2011,12,2011-12-30T05:00:00Z,2011-03-30T03:59:59Z,2011-12-30T13:38:31Z,,0,0,0900006480f8b808
FDA-2011-D-0872-0001,FDA,FDA-2011-D-0872,Draft Guidance for Industry on Use of Histology in Biomarker Qualification Studies; Availabilty,Notice,Notice of Availability,2011-12-30T05:00:00Z,2011,12,2011-12-30T05:00:00Z,2012-03-30T03:59:59Z,2013-11-23T02:02:25Z,2011-33553,0,0,0900006480f8b6cb